Aeterna Zentaris (NASDAQ: AEZS)
Aeterna Zentaris Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Aeterna Zentaris Company Info
Æterna Zentaris, Inc. is a specialty biopharmaceutical company, which engages in the development and commercialization of therapeutics and diagnostic tests. Its product Macimorelin, is an oral growth hormone secretagogue receptor agonist indicated for the diagnosis of Adult Growth Hormone Deficiency. The company was founded on September 12, 1990 and is headquartered in Charleston, SC.
News & Analysis
Tackling Cancer: Your Best Investing Ideas
Following three months of examining the 12 most-diagnosed cancers, these stocks look like your best investment choices.
Tackling Cancer: Endometrial Cancer's Biggest Current and Upcoming Players
Cancer research is big business, and it pays to know where research dollars are headed.
Aeterna Zentaris Names New CEO
David Dodd is tapped to lead the oncology and endocrinology drug development firm.
This Week in Biotech
A look back at the biggest stories this week in biotech and what they mean for investors.
Breakdown of This Biotech Massacre
Why Wall Street ran red with this biotech's blood today.
Will the Feuerstein-Ratain Rule Hold in 2013?
The Feuerstein-Ratain Rule has a perfect record when predicting micro-cap phase 3 trial success. Will it hold against Celsion's pending results in 2013?
Do Orphan Drug Developers Belong in Your Portfolio?
A look into the pros and cons of orphan drug development.
This Week in Biotech
A look back at the biggest stories this week in biotech and what they mean for investors.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.